Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $11.90 Analyst target: $28.09 Upside: 136.05%
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops candidate products using its adeno-associated virus vectors. The company is headquartered in Emeryville, California.
See the full interactive analysis & chart →Informational only — not investment advice.